LT3341368T - Nauji nukleozidų analogai su pakeistu 6-6 bicikliniu aromatiniu žiedu, skirti naudoti kaip prmt5 inhibitoriai - Google Patents
Nauji nukleozidų analogai su pakeistu 6-6 bicikliniu aromatiniu žiedu, skirti naudoti kaip prmt5 inhibitoriaiInfo
- Publication number
- LT3341368T LT3341368T LTEPPCT/EP2016/070097T LT16070097T LT3341368T LT 3341368 T LT3341368 T LT 3341368T LT 16070097 T LT16070097 T LT 16070097T LT 3341368 T LT3341368 T LT 3341368T
- Authority
- LT
- Lithuania
- Prior art keywords
- novel
- aromatic ring
- ring substituted
- bicyclic aromatic
- nucleoside analogues
- Prior art date
Links
- 125000003118 aryl group Chemical group 0.000 title 1
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229940127073 nucleoside analogue Drugs 0.000 title 1
- 101150097768 prmt5 gene Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562209941P | 2015-08-26 | 2015-08-26 | |
| EP15184011 | 2015-09-07 | ||
| US201662306233P | 2016-03-10 | 2016-03-10 | |
| PCT/EP2016/070097 WO2017032840A1 (en) | 2015-08-26 | 2016-08-25 | Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3341368T true LT3341368T (lt) | 2021-12-10 |
Family
ID=54065259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/EP2016/070097T LT3341368T (lt) | 2015-08-26 | 2016-08-25 | Nauji nukleozidų analogai su pakeistu 6-6 bicikliniu aromatiniu žiedu, skirti naudoti kaip prmt5 inhibitoriai |
Country Status (35)
| Country | Link |
|---|---|
| US (4) | US10653711B2 (OSRAM) |
| EP (3) | EP4219496A1 (OSRAM) |
| JP (3) | JP6917978B2 (OSRAM) |
| KR (1) | KR102716092B1 (OSRAM) |
| CN (2) | CN114057815B (OSRAM) |
| AR (1) | AR105820A1 (OSRAM) |
| AU (4) | AU2016311295B2 (OSRAM) |
| BR (2) | BR112018003595B1 (OSRAM) |
| CA (1) | CA2992688A1 (OSRAM) |
| CL (1) | CL2018000510A1 (OSRAM) |
| CO (1) | CO2018002063A2 (OSRAM) |
| CY (1) | CY1125359T1 (OSRAM) |
| DK (1) | DK3341368T3 (OSRAM) |
| EA (1) | EA201890573A1 (OSRAM) |
| ES (1) | ES2901972T3 (OSRAM) |
| HR (1) | HRP20211997T1 (OSRAM) |
| HU (1) | HUE057312T2 (OSRAM) |
| IL (3) | IL311843A (OSRAM) |
| LT (1) | LT3341368T (OSRAM) |
| MA (1) | MA42678B1 (OSRAM) |
| MD (1) | MD3341368T2 (OSRAM) |
| MX (2) | MX392554B (OSRAM) |
| MY (1) | MY198472A (OSRAM) |
| NZ (2) | NZ740528A (OSRAM) |
| PE (2) | PE20180929A1 (OSRAM) |
| PH (2) | PH12018500425B1 (OSRAM) |
| PL (1) | PL3341368T3 (OSRAM) |
| PT (1) | PT3341368T (OSRAM) |
| RS (1) | RS62698B1 (OSRAM) |
| SG (1) | SG10202003775VA (OSRAM) |
| SI (1) | SI3341368T1 (OSRAM) |
| SM (1) | SMT202100725T1 (OSRAM) |
| TN (1) | TN2018000043A1 (OSRAM) |
| TW (3) | TWI791251B (OSRAM) |
| WO (1) | WO2017032840A1 (OSRAM) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI791251B (zh) | 2015-08-26 | 2023-02-01 | 比利時商健生藥品公司 | 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物 |
| ES2891320T3 (es) * | 2016-03-10 | 2022-01-27 | Janssen Pharmaceutica Nv | Análogos de nucleósidos sustituidos para su uso como inhibidores de PRMT5 |
| CA2969295A1 (en) * | 2016-06-06 | 2017-12-06 | Pfizer Inc. | Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| MX392051B (es) | 2016-09-14 | 2025-03-21 | Janssen Pharmaceutica Nv | Inhibidores espirobiciclicos de la interaccion de menina-mll |
| CA3033020A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-mll interaction |
| WO2018065365A1 (en) | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| KR102531344B1 (ko) * | 2016-10-03 | 2023-05-10 | 얀센 파마슈티카 엔.브이. | Prmt5 억제제로서 사용하기 위한 신규의 모노사이클릭 및 바이사이클릭 고리 시스템 치환된 카르바뉴클레오시드 유사체 |
| JP7142010B2 (ja) | 2016-12-15 | 2022-09-26 | ヤンセン ファーマシューティカ エヌ．ベー． | メニン－ｍｌｌ相互作用のアゼパン阻害剤 |
| GB201700526D0 (en) * | 2017-01-12 | 2017-03-01 | Univ Of Hull | Therapeutic use |
| JP7225106B2 (ja) | 2017-02-27 | 2023-02-20 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｐｒｍｔ５阻害剤による治療に応答する癌患者の同定におけるバイオマーカーの使用 |
| BR112020002736A2 (pt) | 2017-08-09 | 2020-07-28 | Prelude Therapeutics, Incorporated | inibidores seletivos da proteína arginina metiltransferase 5 (prmt5) |
| CA3079545A1 (en) | 2017-10-26 | 2019-05-02 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| AU2018381004B2 (en) * | 2017-12-05 | 2021-04-29 | Angex Pharmaceutical, Inc. | Heterocyclic compounds as PRMT5 inhibitors |
| JP7352544B2 (ja) | 2017-12-08 | 2023-09-28 | ヤンセン ファーマシューティカ エヌ．ベー． | 新規なスピロ二環式類似体 |
| AU2018385664B2 (en) | 2017-12-13 | 2022-06-02 | Lupin Limited | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| CA3092357A1 (en) * | 2018-03-14 | 2019-09-19 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| US10711007B2 (en) | 2018-03-14 | 2020-07-14 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
| EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| US20210309687A1 (en) * | 2018-08-07 | 2021-10-07 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| AU2019317549A1 (en) | 2018-08-07 | 2021-02-25 | Msd International Gmbh | PRMT5 inhibitors |
| WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3897667A4 (en) | 2018-12-21 | 2023-04-19 | Memorial Sloan Kettering Cancer Center | SALICYL-ADENOSINE MONOSULFAMATE ANALOGS AND THEIR USES |
| CN109400545B (zh) * | 2018-12-24 | 2022-03-25 | 济南大学 | 一种精氨酸甲基转移酶5抑制剂及其应用 |
| CN109369507A (zh) * | 2018-12-26 | 2019-02-22 | 重庆市碚圣医药科技股份有限公司 | 一种n-(2,2-二乙氧基乙基)邻苯二甲酰亚胺的提纯方法 |
| US20220160713A1 (en) * | 2019-02-13 | 2022-05-26 | Prelude Therapeutics, Incorporated | Selective inhibitor of protein arginine methyltransferase 5 (prmt5) |
| EP3939988A4 (en) * | 2019-03-20 | 2022-08-24 | Korea Research Institute of Chemical Technology | Pharmaceutical composition comprising novel azolopyrimidine heterocyclic compound as active ingredient |
| JP7609798B2 (ja) * | 2019-03-25 | 2025-01-07 | カリフォルニア インスティチュート オブ テクノロジー | Ｐｒｍｔ５インヒビター及びその使用 |
| CA3134613A1 (en) | 2019-04-02 | 2020-10-08 | Aligos Therapeutics, Inc. | Compounds targeting prmt5 |
| US20220152072A1 (en) * | 2019-04-05 | 2022-05-19 | Prelude Therapeutics, Incorporated | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) |
| WO2020206299A1 (en) | 2019-04-05 | 2020-10-08 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 |
| CA3141855A1 (en) * | 2019-05-30 | 2020-12-03 | Angex Pharmaceutical, Inc. | Heterocyclic compounds as prmt5 inhibitors |
| TW202112375A (zh) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | 使用ｐｒｍｔ５抑制劑治療癌症之方法 |
| DK3980417T3 (en) * | 2019-06-10 | 2023-12-18 | Lupin Ltd | PRMT5-Inhibitorer |
| PE20220433A1 (es) | 2019-06-12 | 2022-03-29 | Janssen Pharmaceutica Nv | Intermedios espirobiciclicos novedosos |
| BR112022004630A2 (pt) * | 2019-09-18 | 2022-05-31 | Prelude Therapeutics Inc | Inibidores seletivos da proteína arginina metiltransferase 5 (prmt5) |
| WO2021079196A2 (en) * | 2019-10-21 | 2021-04-29 | Accent Therapeutics, Inc | Mettl3 modulators |
| BR112022007808A2 (pt) * | 2019-10-22 | 2022-07-05 | Lupin Ltd | Combinação farmacêutica de inibidores de prmt5 |
| GB201915447D0 (en) * | 2019-10-24 | 2019-12-11 | Johnson Matthey Plc | Polymorphs of avapritinib and methods of preparing the polymorphs |
| JP7664248B2 (ja) * | 2019-12-03 | 2025-04-17 | ルピン・リミテッド | Ｐｒｍｔ５阻害剤としての置換ヌクレオシドアナログ |
| WO2021126729A1 (en) | 2019-12-17 | 2021-06-24 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| UA129208C2 (uk) | 2019-12-19 | 2025-02-05 | Янссен Фармацевтика Нв | Заміщені спіропохідні з прямим ланцюгом |
| EP4644394A2 (en) | 2020-02-18 | 2025-11-05 | Gilead Sciences, Inc. | Antiviral compounds |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI874791B (zh) | 2020-02-18 | 2025-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| CN111233869B (zh) * | 2020-03-12 | 2022-09-16 | 杭州新博思生物医药有限公司 | 用于制备瑞德西韦关键中间体的新化合物及其制备方法 |
| US20220112194A1 (en) * | 2020-04-01 | 2022-04-14 | Aligos Therapeutics, Inc. | Compounds targeting prmt5 |
| US20240101589A1 (en) * | 2020-10-08 | 2024-03-28 | Strom Therapeutics Limited | Inhibitors of mettl3 |
| CN112645875A (zh) * | 2020-12-09 | 2021-04-13 | 深圳海王医药科技研究院有限公司 | 一种盐酸丙卡特罗杂质的制备方法 |
| KR20230170745A (ko) | 2021-04-16 | 2023-12-19 | 길리애드 사이언시즈, 인코포레이티드 | 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법 |
| CN113234079B (zh) * | 2021-04-30 | 2022-02-01 | 上海湃隆生物科技有限公司 | 用作prmt5抑制剂的核苷类似物 |
| TW202321246A (zh) * | 2021-07-20 | 2023-06-01 | 大陸商上海齊魯製藥研究中心有限公司 | Prmt5抑制劑 |
| CN115703796A (zh) * | 2021-08-09 | 2023-02-17 | 苏州恩泰新材料科技有限公司 | 一种瑞德西韦重要中间体制备方法 |
| WO2023023527A1 (en) | 2021-08-18 | 2023-02-23 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| GB202117230D0 (en) | 2021-11-29 | 2022-01-12 | Argonaut Therapeutics Ltd | Peptide vaccine |
| GB202203588D0 (en) | 2022-03-15 | 2022-04-27 | Argonaut Therapeutics Ltd | Cancer diagnostic |
| CN116655638B (zh) * | 2022-05-12 | 2024-01-26 | 上海齐鲁制药研究中心有限公司 | 氘代prmt5抑制剂 |
| CN116003339B (zh) * | 2022-12-01 | 2024-06-28 | 南京师范大学 | 一种巨噬细胞迁移抑制因子mif双光子荧光探针及其制备方法和应用 |
| WO2024170488A1 (en) | 2023-02-13 | 2024-08-22 | Astrazeneca Ab | Prmt5 inhibitor for use in cancer therapy |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| EP4553080A1 (en) | 2023-11-07 | 2025-05-14 | Ustav Organicke Chemie a Biochemie AV CR, v.v.i. | Nucleoside derivatives as antiviral agents against coronaviruses |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4224438A (en) | 1970-07-14 | 1980-09-23 | Boehringer Mannheim Gmbh | Adenosine-5'-carboxylic acid amides |
| US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| AU2002351077A1 (en) | 2001-11-05 | 2003-05-19 | Exiqon A/S | Oligonucleotides modified with novel alpha-l-rna analogues |
| US7034147B2 (en) | 2001-11-29 | 2006-04-25 | Irm Llc | Nucleoside analog libraries |
| IL163613A0 (en) * | 2002-02-19 | 2005-12-18 | Cv Therapeutics Inc | Partial and full agonists of a1 adenosine receptors |
| US20040043959A1 (en) * | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
| US7144674B2 (en) * | 2002-03-20 | 2006-12-05 | Sumitomo Chemical Company, Limited | Positive resist composition |
| AU2002951247A0 (en) * | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| JPWO2005005450A1 (ja) | 2003-07-15 | 2006-08-24 | 三井化学株式会社 | 環状ビスジヌクレオチドの合成方法 |
| WO2005065150A2 (en) | 2003-12-19 | 2005-07-21 | Koronis Pharmaceuticals, Inc. | Mutagenic heterocycles |
| WO2006078752A2 (en) | 2005-01-21 | 2006-07-27 | Methylgene, Inc. | Inhibitors of dna methyltransferase |
| JP2009542608A (ja) | 2006-06-29 | 2009-12-03 | アステックス・セラピューティクス・リミテッド | 医薬組合せ剤 |
| US20080132525A1 (en) | 2006-12-04 | 2008-06-05 | Methylgene Inc. | Inhibitors of DNA Methyltransferase |
| US8962580B2 (en) | 2008-09-23 | 2015-02-24 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
| CN102803474A (zh) | 2009-12-18 | 2012-11-28 | 哈佛大学校长及研究员协会 | 促进β细胞复制的化合物及其使用方法 |
| CA2819625A1 (en) * | 2010-12-03 | 2012-06-07 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| EP2646455A4 (en) | 2010-12-03 | 2014-04-02 | Epizyme Inc | Modulators of histone methyltransferase, and methods of use thereof |
| CN103354808B (zh) | 2010-12-16 | 2016-08-10 | Abbvie公司 | 抗病毒化合物 |
| EP2694524B1 (en) | 2011-04-04 | 2016-05-18 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | 2'-o-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides |
| EP2771012A4 (en) | 2011-10-24 | 2015-06-24 | Glaxosmithkline Ip No 2 Ltd | NEW CONNECTIONS |
| WO2013151975A1 (en) | 2012-04-02 | 2013-10-10 | Northeastern University | Compositions and methods for the inhibition of methyltransferases |
| WO2014035140A2 (en) | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Compounds and compositions for modulating histone methyltransferase activity |
| US20140100184A1 (en) | 2012-08-31 | 2014-04-10 | Baylor College Of Medicine | Selective inhibitors of histone methyltransferase dot1l |
| JP2016505001A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| US9908887B2 (en) * | 2012-12-21 | 2018-03-06 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| HUE040323T2 (hu) | 2012-12-21 | 2019-02-28 | Epizyme Inc | PRMT5-inhibitorok és alkalmazásaik |
| EP2935243B1 (en) | 2012-12-21 | 2018-03-14 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| US9856218B2 (en) | 2013-03-15 | 2018-01-02 | Ohio State Innovation Foundation | Inhibitors of PRMT5 and methods of their use |
| EP3091984B1 (en) | 2014-01-09 | 2020-04-22 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Substituted benzoxazine and related compounds |
| WO2015200680A2 (en) | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| HRP20191979T1 (hr) | 2014-07-01 | 2020-02-07 | Millennium Pharmaceuticals, Inc. | Heteoarilni spojevi koji su korisni kao inhibitori sumo-aktivirajućeg enzima |
| CN107278205A (zh) | 2015-02-24 | 2017-10-20 | 辉瑞大药厂 | 用作抗癌药的取代的核苷衍生物 |
| TWI791251B (zh) * | 2015-08-26 | 2023-02-01 | 比利時商健生藥品公司 | 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物 |
| KR20180116307A (ko) | 2016-03-10 | 2018-10-24 | 얀센 파마슈티카 엔.브이. | Prmt5 저해제로 사용하기 위한 치환 뉴클레오사이드 유사체 |
| WO2018065365A1 (en) | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| KR102531344B1 (ko) * | 2016-10-03 | 2023-05-10 | 얀센 파마슈티카 엔.브이. | Prmt5 억제제로서 사용하기 위한 신규의 모노사이클릭 및 바이사이클릭 고리 시스템 치환된 카르바뉴클레오시드 유사체 |
| JP7225106B2 (ja) | 2017-02-27 | 2023-02-20 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｐｒｍｔ５阻害剤による治療に応答する癌患者の同定におけるバイオマーカーの使用 |
| JP7352544B2 (ja) | 2017-12-08 | 2023-09-28 | ヤンセン ファーマシューティカ エヌ．ベー． | 新規なスピロ二環式類似体 |
-
2016
- 2016-08-24 TW TW110127686A patent/TWI791251B/zh active
- 2016-08-24 TW TW112102610A patent/TWI870767B/zh active
- 2016-08-24 TW TW105126988A patent/TWI730980B/zh active
- 2016-08-25 PH PH1/2018/500425A patent/PH12018500425B1/en unknown
- 2016-08-25 PL PL16757233T patent/PL3341368T3/pl unknown
- 2016-08-25 ES ES16757233T patent/ES2901972T3/es active Active
- 2016-08-25 CN CN202111120182.2A patent/CN114057815B/zh active Active
- 2016-08-25 PH PH1/2021/552054A patent/PH12021552054A1/en unknown
- 2016-08-25 LT LTEPPCT/EP2016/070097T patent/LT3341368T/lt unknown
- 2016-08-25 CN CN201680048987.1A patent/CN107922413B/zh active Active
- 2016-08-25 PE PE2018000306A patent/PE20180929A1/es unknown
- 2016-08-25 BR BR112018003595-5A patent/BR112018003595B1/pt active IP Right Grant
- 2016-08-25 SI SI201631402T patent/SI3341368T1/sl unknown
- 2016-08-25 NZ NZ740528A patent/NZ740528A/en unknown
- 2016-08-25 NZ NZ779003A patent/NZ779003A/en unknown
- 2016-08-25 MA MA42678A patent/MA42678B1/fr unknown
- 2016-08-25 US US15/755,475 patent/US10653711B2/en active Active
- 2016-08-25 WO PCT/EP2016/070097 patent/WO2017032840A1/en not_active Ceased
- 2016-08-25 CA CA2992688A patent/CA2992688A1/en active Pending
- 2016-08-25 MY MYPI2018000274A patent/MY198472A/en unknown
- 2016-08-25 HU HUE16757233A patent/HUE057312T2/hu unknown
- 2016-08-25 KR KR1020187007810A patent/KR102716092B1/ko active Active
- 2016-08-25 RS RS20211526A patent/RS62698B1/sr unknown
- 2016-08-25 EP EP23162887.6A patent/EP4219496A1/en active Pending
- 2016-08-25 EA EA201890573A patent/EA201890573A1/ru unknown
- 2016-08-25 DK DK16757233.8T patent/DK3341368T3/da active
- 2016-08-25 SG SG10202003775VA patent/SG10202003775VA/en unknown
- 2016-08-25 EP EP21199207.8A patent/EP3974428A1/en active Pending
- 2016-08-25 BR BR122023020317-8A patent/BR122023020317A2/pt not_active Application Discontinuation
- 2016-08-25 MD MDE20180642T patent/MD3341368T2/ro unknown
- 2016-08-25 PT PT167572338T patent/PT3341368T/pt unknown
- 2016-08-25 IL IL311843A patent/IL311843A/en unknown
- 2016-08-25 JP JP2018510334A patent/JP6917978B2/ja active Active
- 2016-08-25 EP EP16757233.8A patent/EP3341368B1/en active Active
- 2016-08-25 AU AU2016311295A patent/AU2016311295B2/en active Active
- 2016-08-25 HR HRP20211997TT patent/HRP20211997T1/hr unknown
- 2016-08-25 AR ARP160102600A patent/AR105820A1/es active IP Right Grant
- 2016-08-25 SM SM20210725T patent/SMT202100725T1/it unknown
- 2016-08-25 PE PE2022000450A patent/PE20221629A1/es unknown
- 2016-08-25 MX MX2018002326A patent/MX392554B/es unknown
- 2016-08-25 TN TNP/2018/000043A patent/TN2018000043A1/en unknown
-
2018
- 2018-02-21 IL IL257664A patent/IL257664B/en active IP Right Grant
- 2018-02-23 MX MX2022005182A patent/MX2022005182A/es unknown
- 2018-02-26 CL CL2018000510A patent/CL2018000510A1/es unknown
- 2018-02-26 CO CONC2018/0002063A patent/CO2018002063A2/es unknown
-
2020
- 2020-03-20 US US16/825,024 patent/US11318157B2/en active Active
-
2021
- 2021-01-20 AU AU2021200345A patent/AU2021200345B2/en active Active
- 2021-04-21 IL IL282537A patent/IL282537A/en unknown
- 2021-07-20 JP JP2021120042A patent/JP7720732B2/ja active Active
-
2022
- 2022-01-04 CY CY20221100008T patent/CY1125359T1/el unknown
- 2022-03-09 US US17/690,587 patent/US11883367B2/en active Active
- 2022-08-11 AU AU2022215260A patent/AU2022215260B2/en active Active
-
2023
- 2023-03-21 US US18/187,463 patent/US20230330127A1/en not_active Abandoned
- 2023-10-27 JP JP2023184701A patent/JP2024012405A/ja not_active Withdrawn
-
2024
- 2024-03-28 AU AU2024202052A patent/AU2024202052A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282537A (en) | Novel 6–6 bicyclic aromatic ring-converted nucleoside analogs for use as PRMT5 inhibitors | |
| IL261559A (en) | Nucleoside analogues are converted for use as prmt5 inhibitors | |
| IL288519A (en) | inhibitors of ret | |
| IL286428A (en) | Disubstituted heterocyclyl derivatives as inhibitors of cyclin-dependent kinases | |
| ZA201800480B (en) | New bicyclic compounds as dual atx/ca inhibitors | |
| ZA201801032B (en) | Bicyclic compounds as atx inhibitors | |
| ZA202003528B (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
| IL255570A (en) | Bicyclic compounds as atx inhibitors | |
| IL255511B (en) | New bicyclic compounds as dual atx/ca inhibitors | |
| EP3212657A4 (en) | Methods of preparing substituted nucleoside analogs | |
| IL249456A0 (en) | Methods for preparing analogues of modified nucleotides | |
| IL265718B (en) | Novel modified carbonucleoside analogs with monocyclic and cyclic ring systems as prmt5 inhibitors | |
| HUE053463T2 (hu) | Pirrolopirimidin vegyületek, amelyek használhatók JAK inhibitorokként | |
| IL255357A0 (en) | bicyclic compounds | |
| IL256226A (en) | Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors | |
| HK40067051A (zh) | 作为prmt5抑制剂的、新颖6-6二环芳环取代的核苷 | |
| ZA201806016B (en) | Substituted nucleoside analogues for use as prmt5 inhibitors |